Studies new ways to detect harmful lung bacteria in people with cystic fibrosis
Looks for better ways to find harmful lung bacteria in people with cystic fibrosis.
Key facts
- Who runs it
- Chris Goss
- Where
- Columbus, Dallas, La Jolla, Milwaukee, Minneapolis, Omaha, Philadelphia, Pittsburgh, and St Louis, United StatesSee the 9 sites
- Trial code
- Registry title
- Study to Enable New Diagnostics for Pulmonary Microbes in People With CF
- Status
- Recruiting
- People taking part
- 300 people, planned
- Started
- 30 Mar 2026
- Expected to end
- 1 Aug 2027
- Type of study
- Observational
- Record updated
- 2 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with cystic fibrosis who are 16 or older and can cough up sputum. It tests new ways to find harmful lung bacteria.
- Age
- 16 years or older
- Sex
- All sexes
- Disease stage
- Cystic fibrosis with a documented diagnosis. Percent predicted FEV1 must be 30% or higher.
Main reasons for not taking part
- History of solid organ transplant
- Active cancer, or cancer treatment, in the 12 months before the study visit
- Pregnant
- Cannot cough up sputum
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- ≥ 16 years of age on day of study visit
- Documentation of CF Diagnosis
- Able to expectorate sputum
- Percent predicted FEV1 ≥ 30%
Who cannot take part
- History of active malignancy (or treatment for malignancy) in 12 months prior to the study visit
- History of solid organ transplantation
- Pregnant
Where in United States
- Nationwide Children's HospitalColumbus, United StatesContact: Diana GilmoreNot yet recruiting
- University of Texas, SouthwesternDallas, United StatesContact: Ashley KellerTaking people
- University of California San DiegoLa Jolla, United StatesContact: Jenna MielkeNot yet recruiting
- Froedtert & Medical College of WisconsinMilwaukee, United StatesContact: Erin HubertzTaking people
- The Minnesota Cystic Fibrosis CenterMinneapolis, United StatesContact: Nikita MidambaTaking people
- University of Nebraska Medical CenterOmaha, United StatesContact: Michel VeitNot yet recruiting
- University of PennsylvaniaPhiladelphia, United StatesContact: Melissa MolterTaking people
- University of Pittsburgh Medical CenterPittsburgh, United StatesContact: Adrienne DeRiccoTaking people
- Washington University School of MedicineSt Louis, United StatesContact: Irma BauerTaking people
About the trial
What the trial wants to find out
Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is more difficult for people with CF to produce sputum even though they still have harmful bacteria in their lungs. The SEND-CF study is being done to see if there are other ways to detect harmful bacteria in the lungs.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Study to Enable New Diagnostics for Pulmonary Microbes in People With CF (SEND-CF)
- Plain-language title
- Studies new ways to detect harmful lung bacteria in people with cystic fibrosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 2 July 2026